Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Meihao Medical Group Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -21.57%.
Meihao Medical Group Co (HKSE:01947) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meihao Medical Group Co (HKSE:01947) has a ROCE % of -21.57% as of Dec. 2025.
Is Meihao Medical Group Co's ROCE % too high?
Meihao Medical Group Co's current ROCE % is -21.57%. Overall, Meihao Medical Group Co has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Meihao Medical Group Co's ROCE % compare to HCA and THC?
Meihao Medical Group Co's ROCE % of -21.57% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.32, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meihao Medical Group Co's current ROCE % is -21.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meihao Medical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Meihao Medical Group Co (HKSE:01947) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.40, compared to a current price of HK$0.59 — trading 46.3% above its estimated fair value. The current ROCE % is -21.57%. Meihao Medical Group Co's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Meihao Medical Group Co (HKSE:01947), the current ROCE % is -21.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meihao Medical Group Co (HKSE:01947) Overvalued in 2026?
Based on GuruFocus' analysis, Meihao Medical Group Co stock appears to be overvalued.
The current stock price of HK$0.59 is trading 46.3% above its estimated GF Value™ of HK$0.40.
GuruFocus considers Meihao Medical Group Co to be Significantly Overvalued.
Key valuation signals for HKSE:01947:
ROCE %: -21.57%
GF Value™: HK$0.40 vs. price of HK$0.59 (46.3% above fair value)
No single metric tells the full story. See the HKSE:01947 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meihao Medical Group Co Ltd is a dental service provider in Wenzhou. It offers services to individuals and covers principally four dental sectors: general dentistry, reparative dentistry, implant dentistry, orthodontics, and cosmetic dentistry. The company generates all of its revenue from Mainland China from dental services.
48GF Score
Get the complete analysis for HKSE:01947
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01947 has been successfully added to your 
